Neuralert News

FDA awards Neuralert Technologies Breakthrough Device designation

July 29, 2021

Philadelphia, PA – The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has granted the Neuralert Monitor designation as a Breakthrough Device. The Neuralert Technologies device is indicated for use to “detect the onset of asymmetric movement in hospitalized patients with medical conditions or procedures that are established risks for stroke and who have no baseline asymmetric upper extremity weakness."

Neuralert is a spin-out from the University of Pennsylvania, founded by Steven Messé, MD (Department of Neurology) and James Weimer, PhD (Department of Computer and Information Science). The company’s novel invention addresses the problem of late or undetected stroke in hospitalized patients. The system uses non-invasive, wearable devices which continuously monitor at-risk hospitalized patients for stroke symptoms and automatically alerts clinical staff resulting in more rapid assessment and treatment of the patient. Neuralert’s automated detection process may be up to ten times faster when compared to the current standard of care which relies on manual detection processes. Reduction in stroke detection time will save patient lives, improve outcomes, and reduce hospital cost and liability.

“Currently, hospital stroke detection requires consistent, timely, and effective manual assessment. Unfortunately, the majority of in-hospital strokes are not detected in a timely manner resulting in treatment delays which adversely impact patient outcomes and hospital cost” said Eric Corkhill, CEO of Neuralert. “Neuralert is an automated stroke symptom detection system which constantly monitors the patient for stroke-based asymmetry, a revolutionary change in managing stroke. FDA granting Neuralert Breakthrough Device designation is a major milestone in our efforts to bring this valuable and revolutionary technology to market.”

Learn More

Neuralert selected for University City Science Center Accelerator and Funding up to $50,000

April 1, 2021

Philadelphia, PA – Neuralert Technologies LLC (www.neuralerttechnologies.com) was one of eight startups from the U.S. and Canada selected for the latest iteration of University City Science Center Launch Lane Accelerator. This is the fifth cohort for Launch Lane (formerly the Digital Health Accelerator (DHA)). Launch Lane focuses on the equitable sourcing of companies, with the selection process utilizing a blind application to eliminate biases.

Neuralert is a spin-out from the University of Pennsylvania, founded by Steven Messe, MD (Department of Neurology) and James Weimer, PhD (Department of Computer and Information Science). The company’s novel invention addresses the problem of late or undetected stroke in hospitalized patients. The system uses non-invasive, wearable devices which accurately detect stroke symptoms and then alerts clinical staff to more rapidly initiate stroke mitigating treatments. Neuralert decreases stroke detection time by over 400% compared to the current standard of care saving patient lives, improving outcomes, and reducing hospital costs and liability.

“Currently, hospital stroke detection requires consistent, timely, and effective manual assessment. Unfortunately, the majority of in-hospital strokes are not detected in a timely manner resulting in treatment delays which adversely impacts patient outcomes and hospital cost” said Eric Corkhill. CEO of Neuralert. “Neuralert is an automated stroke detection system which constantly monitors the patient for stroke-based asymmetry, a revolutionary change in managing stroke. Funding from the Science Center’s Launch Lane Accelerator will significantly help us to operationalize the product. In addition to their investment, I look forward to participating programming tailored to our growth needs and access to the Science Center’s vast network of connections and resources.”

Learn More

Neuralert receives $25,000 funding from Bucks Built Startup Fund

February 17, 2021

Philadelphia, PA – Neuralert Technologies LLC (www.neuralerttechnologies.com) was one of five recipients in the inaugural batch of the Bucks Built Accelerator Fund, a program administered by Startup Bucks and funded by the County of Bucks. Startup Bucks, a 501(c)3 organization founded in 2019, exists to help innovative companies start, grow, and scale in and beyond Bucks County by supporting founders and connecting the startup ecosystem across and beyond the County.

Neuralert is a spin-out from the University of Pennsylvania, founded by Steven Messe, MD (Department of Neurology) and James Weimer, PhD (Department of Computer and Information Science). The company addresses the problem of late or undetected stroke in hospitalized patients using non-invasive, wearable devices. These devices accurately detect stroke symptoms and alert clinical staff to more rapidly initiate stroke mitigating treatments. Neuralert dramatically reduces the time to detect stroke symptoms, saving patient lives, improving outcomes, and reducing hospital costs and liability.

“Neuralert can help end the devastation caused by in-hospital strokes. Automating detection decreases the current delay between a stroke event and treatment allowing the hospital to utilize proven lifesaving and stroke mitigating treatments” said Eric Corkhill, CEO of Neuralert Technologies. “The $25,000 investment and ongoing support from Buck Built will help us to perform additional testing which will refine our product and position us for near term commercial growth”.

Learn More

Neuralert awarded Ben Franklin PRIMA Grant

October 2, 2020

Philadelphia, PA Neuralert Technologies LLC (www.neuralerttechnologies.com) has been awarded PRIMA (Philadelphia Regional Integrated Medicine Alliance) Grant funding by Ben Franklin Technology Partners of Southeastern PA. PRIMA links discovery, infrastructure, information and analysis systems and commercialization resources to enable startups, large companies, universities, hospitals, and other nonprofit organizations and regional life science stakeholders to collaborate to accelerate technology innovation and reduce barriers to commercialization.

Neuralert is a spin-out from the University of Pennsylvania, founded by Steven Messe, MD (Department of Neurology) and James Weimer, PhD (Department of Computer and Information Science). The company focuses on early detection of stroke symptoms in hospitalized patients via smart, non-invasive, wearable devices. Its innovative platform can accurately detect these symptoms and immediately alert clinical staff to assess the patient and initiate stroke mitigating treatments. Neuralert dramatically reduces the time to detect stroke symptoms, saving patient lives, improving outcomes and reducing hospital costs and liability.

“We believe we can end the devastation caused by in-hospital strokes. Using an automated method like Neuralert to monitor post-surgical patients as well as patients with elevated stroke risk, decreases the delay between a stroke event and treatment” said Eric Corkhill, CEO of Neuralert Technologies. “Ben Franklin PRIMA Grant funding will help us to port our technology to a stable, secure infrastructure utilizing Amazon Web Services.

Learn More

Neuralert selected for NextFab RAPID Hardware Accelerator

September 28, 2020

Philadelphia, PA Neuralert Technologies LLC (www.neuralerttechnologies.com) has been selected to participate in the Fall 2020 NextFab Studio LLC RAPID Hardware Accelerator program. NextFab is a pre-seed stage hardware-focused investor and a network of makerspaces in the Greater Philadelphia area.

Neuralert is a spin-out from the University of Pennsylvania, founded by Steven Messe, MD (Department of Neurology) and James Weimer, PhD (Department of Computer and Information Science). The company focuses on early detection of stroke symptoms in hospitalized patients via smart, non-invasive, wearable devices. Its innovative platform can accurately detect these symptoms and immediately alert clinical staff to assess the patient and initiate stroke mitigating treatments. Neuralert dramatically reduces the time to detect stroke symptoms, saving patient lives, improving outcomes and reducing hospital costs and liability.

As part of the RAPID Accelerator's Fall 2020 cohort, Neuralert will receive hands-on technical product development support, seed capital, business coaching, and access to manufacturing and prototyping equipment at NextFab.

“We believe we can end the devastation caused by in-hospital strokes. Using an automated method like Neuralert to monitor post-surgical patients as well as patients with elevated stroke risk, decreases the delay between a stroke event and treatment” said Eric Corkhill, CEO of Neuralert Technologies. “NextFab will help us to create purpose-built, wearable devices designed to operate within the complexities of the clinical environment while ensuring high adoption by both patients and staff”.

Learn More